for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oncolytics Biotech, Inc. (USA)

ONCY.O

Latest Trade

0.48USD

Change

0.05(+10.56%)

Volume

152,430

Today's Range

0.46

 - 

0.52

52 Week Range

0.35

 - 

3.64

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest News

BRIEF-Oncolytics Biotech Announces A Master Clinical Supply Agreement Of An Anti-PD-L1 Checkpoint Inhibitor

* ONCOLYTICS BIOTECH® ANNOUNCES A MASTER CLINICAL SUPPLY AGREEMENT OF AN ANTI-PD-L1 CHECKPOINT INHIBITOR FOR USE IN THE COMPANY’S CLINICAL PROGRAM

BRIEF-Oncolytics Biotech Says Has Applied To List Its Common Shares On Nasdaq

* ONCOLYTICS BIOTECH® HAS APPLIED TO LIST ITS COMMON SHARES ON NASDAQ AND ANNOUNCES SHARE CONSOLIDATION

BRIEF-Oncolytics Biotech® Announces Collaboration With Merck And Northwestern University

* ONCOLYTICS BIOTECH® ANNOUNCES COLLABORATION WITH MERCK AND NORTHWESTERN UNIVERSITY COMBINING KEYTRUDA® AND REOLYSIN® IN A PHASE 2 SECOND LINE PANCREATIC CANCER STUDY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Oncolytics Biotech Receives Special Protocol Assessment Agreement From FDA For Phase 3 Clinical Trial Of Pelareorep In Metastatic Breast Cancer

* ONCOLYTICS BIOTECH® RECEIVES SPECIAL PROTOCOL ASSESSMENT AGREEMENT FROM FDA FOR PHASE 3 CLINICAL TRIAL OF PELAREOREP IN METASTATIC BREAST CANCER Source text for Eikon: Further company coverage:

BRIEF-Oncolytics Biotech Files For Mixed Shelf Of Up To C$150 Mln

* ONCOLYTICS BIOTECH INC FILES FOR MIXED SHELF OF UP TO C$150 MILLION – SEC FILING Source text: (https://bit.ly/2qZfCr2) Further company coverage:

Biotech CEO, two associates accused by U.S. of securities fraud

The chief executive of a biotech company that said it was developing a non-opiate pain treatment was arrested along with two associates on Tuesday on U.S. charges that he misled investors and participated in a stock manipulation scheme.

BRIEF-Oncolytics Biotech Chief Medical Officer To Leave Effective April 23

* ONCOLYTICS BIOTECH INC - ANDRES GUTIERREZ, CHIEF MEDICAL OFFICER WILL BE LEAVING EFFECTIVE APRIL 23, 2018 Source text for Eikon: Further company coverage:

BRIEF-Oncolytics Biotech Inc Announces 2017 Year-End Results

* ONCOLYTICS BIOTECH INC - AT DECEMBER 31, 2017, THE COMPANY REPORTED $11.8 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Source text for Eikon: Further company coverage:

BRIEF-Oncolytics Biotech Receives Shareholder Approval To Consolidate Company's Common Shares At Its February 23, 2018 Special Meeting Of Shareholders

* ONCOLYTICS BIOTECH INC - RECEIVED SHAREHOLDER APPROVAL TO CONSOLIDATE COMPANY'S COMMON SHARES AT ITS FEBRUARY 23, 2018 SPECIAL MEETING OF SHAREHOLDERS Source text for Eikon: Further company coverage:

BRIEF-Oncolytics Biotech Plans To Apply To List Common Shares On Nasdaq Capital Market

* ONCOLYTICS BIOTECH® INC. ANNOUNCES PLANS TO APPLY TO LIST COMMON SHARES ON THE NASDAQ CAPITAL MARKET Source text for Eikon: Further company coverage:

BRIEF-Oncolytics Biotech Receives Final Advice Letter From European Medicines Agency For Reolysin In Metastatic Breast Cancer

* ONCOLYTICS BIOTECH® RECEIVES FAVORABLE FINAL ADVICE LETTER FROM THE EUROPEAN MEDICINES AGENCY FOR REOLYSIN® IN METASTATIC BREAST CANCER

BRIEF-Oncolytics Biotech and Adlai Nortye enter into $86.6 mln regional licensing agreement for Reolysin

* Oncolytics Biotech® Inc. and Adlai Nortye enter into $86.6 million regional licensing agreement for Reolysin®

BRIEF-Oncolytics Biotech Inc reports qtrly share of $0.02

* Oncolytics Biotech Inc. announces 2017 third quarter results

BRIEF-Oncolytics announces successful end-of-Phase 2 meeting with FDA for reolysin

* Oncolytics Biotech Inc - announces successful end-of-Phase 2 meeting with FDA for reolysin in metastatic breast cancer

BRIEF-Oncolytics Biotech announces first patient treated in Muk Eleven study

* Oncolytics Biotech announces first patient treated in muk eleven study

BRIEF-‍Krystal Biotech Inc files to say it has raised $11.3 million in equity financing - SEC Filing ​

* Krystal Biotech Inc files to say it has raised $11.3 million in equity financing from total offering amount of $11.3 million - SEC Filing Source text: (http://bit.ly/2fTu95H)

BRIEF-Sun Pharmaceutical Industries says unit to acquire 15.91 pct diluted stake of Krystal Biotech

* Unit agreed to acquire by way of allotment 203,135 series A preferred stock of Krystal Biotech Inc for $7 million Source text: (http://bit.ly/2vi3zH0) Further company coverage:

BRIEF-Oncolytics Biotech Inc's qtrly loss per share $0.03

* Oncolytics Biotech Inc announces 2017 second quarter results

BRIEF-Oncolytics Biotech granted end-of-phase 2 meeting with FDA

* Oncolytics biotech® to present reolysin® safety data in combination with chemotherapy at esmo 2017 congress

BRIEF-ONCOLYTICS BIOTECH PRICES PUBLIC OFFERING OF 14.3 MILLION AT C$0.70/UNIT

* SAYS PUBLIC OFFERING OF 14.3 MILLION UNITS PRICED AT C$0.70/UNIT Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up